NASDAQ:TBIO Telesis Bio (TBIO) Stock Price, News & Analysis → Democrats’ “break glass for emergency” candidate for 2024 (From The Freeport Society) (Ad) Free TBIO Stock Alerts $4.40 +0.06 (+1.38%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$4.11▼$4.6750-Day Range$3.03▼$7.9252-Week Range$3.03▼$39.24Volume44,528 shsAverage Volume33,381 shsMarket Capitalization$7.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends Get Telesis Bio alerts: Email Address Ad The Freeport SocietyThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. How is this possible, with Biden so unpopular, and Trump running at least neck-in-neck with him in polls?This presentation explains exactly why. About Telesis Bio Stock (NASDAQ:TBIO)Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.Read More TBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TBIO Stock News HeadlinesMay 10, 2024 | investorplace.comTBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comTelesis Bio Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comTelesis Bio Announces Reverse Stock SplitApril 20, 2024 | uk.investing.comTelesis Bio appoints new CEO as founder steps downApril 18, 2024 | msn.comTelesis Bio announces leadership transition amid new commercial focusApril 18, 2024 | globenewswire.comTelesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadershipMarch 29, 2024 | msn.comTBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q4 2023March 28, 2024 | globenewswire.comTelesis Bio Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 3, 2024 | morningstar.comTelesis Bio Inc TBIOFebruary 26, 2024 | finance.yahoo.comTelesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial ResultsFebruary 26, 2024 | globenewswire.comTelesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial ResultsFebruary 24, 2024 | benzinga.comTelesis Bio Stock (NASDAQ:TBIO), Insider Trading ActivityFebruary 23, 2024 | investorplace.comWhy Is Telesis Bio (TBIO) Stock Up 29% Today?February 23, 2024 | msn.comToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayFebruary 18, 2024 | finance.yahoo.comTelesis Bio, Inc. (TBIO)February 6, 2024 | finance.yahoo.comTelesis Bio, Inc.'s (NASDAQ:TBIO) Shares Leap 38% Yet They're Still Not Telling The Full StoryFebruary 6, 2024 | finance.yahoo.comBeat the Market the Zacks Way: Hershey's, Telesis Bio, General Mills in FocusFebruary 6, 2024 | finance.yahoo.comTelesis Bio (TBIO) Reports Q1 Loss, Misses Revenue EstimatesFebruary 6, 2024 | finance.yahoo.comTelesis Bio First Quarter 2023 Earnings: EPS Beats Expectations, Revenues LagFebruary 6, 2024 | finance.yahoo.comThis Telesis Bio Insider Increased Their Holding In The Last YearJanuary 22, 2024 | msn.comToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayNovember 13, 2023 | msn.comTelesis Bio GAAP EPS of -$0.37, revenue of $5.6MNovember 13, 2023 | msn.comTelesis Bio GAAP EPS of -$0.37 misses by $0.04, revenue of $5.6M misses by $1.8MAugust 30, 2023 | markets.businessinsider.comTelesis Bio Appoints William Kullback CFOAugust 29, 2023 | seekingalpha.comTelesis Bio appoints William Kullback as CFOSee More Headlines Receive TBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/14/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:TBIO Previous SymbolNASDAQ:DNAY CUSIPN/A CIK1850079 Webtelesisbio.com Phone858-228-4115FaxN/AEmployees137Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($28.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,720,000.00 Net Margins-183.66% Pretax Margin-183.57% Return on Equity-359.32% Return on Assets-38.33% Debt Debt-to-Equity Ratio22.76 Current Ratio3.65 Quick Ratio3.08 Sales & Book Value Annual Sales$24.63 million Price / Sales0.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book31.43Miscellaneous Outstanding Shares1,683,000Free Float1,271,000Market Cap$7.41 million OptionableOptionable Beta1.76 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Eric Esser (Age 55)President, CEO, COO & Director Comp: $429.11kDr. Todd R. Nelson MBA (Age 57)Ph.D., Founder & Director Comp: $621.61kMr. Robert H. Cutler (Age 56)Chief Legal Officer Comp: $413.34kMr. William J. Kullback (Age 64)Chief Financial Officer Mr. Daniel G. Gibson Ph.D. (Age 47)Chief Technology Officer Comp: $590.37kMs. Jen CarrollVice President of Investor RelationsMr. Decky Goodrich M.B.A.Senior Vice President of Corporate DevelopmentRichard LepkeDirector of Investor RelationsMore ExecutivesKey CompetitorsAccelerate DiagnosticsNASDAQ:AXDXSingular Genomics SystemsNASDAQ:OMICTalis BiomedicalNASDAQ:TLISAstrotechNASDAQ:ASTCPrecipioNASDAQ:PRPOView All Competitors TBIO Stock Analysis - Frequently Asked Questions How have TBIO shares performed in 2024? Telesis Bio's stock was trading at $7.1820 at the beginning of the year. Since then, TBIO shares have decreased by 38.7% and is now trading at $4.40. View the best growth stocks for 2024 here. Are investors shorting Telesis Bio? Telesis Bio saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 31,700 shares, an increase of 81.1% from the May 15th total of 17,500 shares. Based on an average trading volume of 20,400 shares, the days-to-cover ratio is presently 1.6 days. Currently, 6.9% of the shares of the stock are short sold. View Telesis Bio's Short Interest. When is Telesis Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our TBIO earnings forecast. How were Telesis Bio's earnings last quarter? Telesis Bio, Inc. (NASDAQ:TBIO) released its earnings results on Thursday, May, 9th. The company reported ($99.28) earnings per share for the quarter. The firm earned $3.44 million during the quarter, compared to analysts' expectations of $6.90 million. Telesis Bio had a negative trailing twelve-month return on equity of 359.32% and a negative net margin of 183.66%. When did Telesis Bio's stock split? Telesis Bio shares reverse split before market open on Thursday, May 9th 2024. The 1-18 reverse split was announced on Thursday, May 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What is Craig J. Tuttle's approval rating as Telesis Bio's CEO? 13 employees have rated Telesis Bio Chief Executive Officer Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among the company's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Telesis Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Telesis Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv). When did Telesis Bio IPO? Telesis Bio (TBIO) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Telesis Bio? Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TBIO) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telesis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.